GNCA

Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.